Disclaimer: Due to limited expertise, errors are inevitable, and some information may not be the most up-to-date; feedback in the comments is welcome. This article is only an introduction to medical and health-related drugs, not a recommendation of treatment options (if involved); it does not constitute any investment advice.
On May 7, China BioTech Services (08037) announced that its indirectly non-wholly owned subsidiary, Shanghai Longyao Biological Technology Co., LTD, will present the Phase I clinical trial results of LY007 Cell Injection at the 18th International Conference on Malignant Lymphoma from June 17 to June 21, 2025, and at the 30th European Hematology Association Annual Congress from June 12 to June 15.This product is a novel autologous chimeric antigen receptor T-cell therapy targeting the CD20 antigen, designed for patients with relapsed or refractory B-cell non-Hodgkin lymphoma. According to the announcement, among 12 patients with relapsed/refractory CD20-positive B-cell non-Hodgkin lymphoma treated with LY007, 92% experienced tumor reduction or disappearance, with the best complete response rate reaching 75%.In addition, LY007 offers a new treatment option for patients who have failed CD19 CAR-T therapy or experienced CD19-negative relapse, with its CAR-T cells reaching a peak expansion of 46% to 80% of CD3+ T cells in patients. Shanghai Longyao Biological Technology Co., LTD plans to further advance the international multicenter clinical research of LY007 at international conferences and has already filed 14 global patents to support product commercialization and expansion into solid tumor indications.Source of the article: Company Announcement
